Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Daniel R. Principe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4355-6597; OpenAlex author ID A5077861885; NIH RePORTER profile ID 15400378. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
34
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 1 grant · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 18

  1. The immunobiology of pancreatic cancer metastasis: premetastatic niche formation, organ-specific immune landscapes, and therapeutic opportunities. Co-author DOI 10.1007/s10555-026-10334-1↗
  2. Humoral immunity in pancreatic cancer: B-cell heterogeneity, regulatory networks, and therapeutic opportunities. Last author DOI 10.1007/s10555-026-10342-1↗
  3. Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3574↗
  4. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2116764119↗
  5. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Co-author DOI 10.1073/pnas.2200143119↗
  6. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.806963↗
  7. Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. Co-author DOI 10.3390/cancers14040897↗
  8. Trials and tribulations of pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.canlet.2021.01.031↗
  9. Mixed Lineage Kinase 3 phosphorylates prolyl-isomerase PIN1 and potentiates GLI1 signaling in pancreatic cancer development. Co-author DOI 10.1016/j.canlet.2021.04.015↗
  10. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Co-author DOI 10.3389/fonc.2021.688377↗
  11. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Co-author DOI 10.3390/cancers13030440↗
  12. Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. Co-author DOI 10.1016/j.canlet.2020.04.022↗
  13. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-18-0850↗
  14. TM4SF18 is aberrantly expressed in pancreatic cancer and regulates cell growth. Co-author DOI 10.1371/journal.pone.0211711↗
  15. KRAS G12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Co-author DOI 10.1038/s41598-018-30916-6↗
  16. The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170616111225↗
  17. HDAC3 mediates smoking-induced pancreatic cancer. Co-author DOI 10.18632/oncotarget.6820↗
  18. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. First author DOI 10.3389/fphys.2014.00464↗

Grants 1

  1. Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition F30CA236031↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidayatullah G. Munshi · 9 shared papers, 2018–2024 · strength 1.28
  2. Ajay Nmn Rana · 9 shared papers, 2018–2022 · strength 1.27
  3. Patrick W. Underwood · 5 shared papers, 2021–2022 · strength 0.72
  4. Thao D. Pham · 4 shared papers, 2021–2024 · strength 0.63
  5. Paul J. Grippo · 7 shared papers, 2014–2021 · strength 0.60
  6. Jose Gilberto Trevino · 4 shared papers, 2021–2022 · strength 0.58
  7. Sandeep Kumar · 4 shared papers, 2019–2022 · strength 0.51
  8. Joshua Kalapala · 1 shared paper, 2026 · strength 0.43
  9. Mario A. Shields · 2 shared papers, 2021–2024 · strength 0.36
  10. Murray Korc · 2 shared papers, 2021 · strength 0.33
  11. Suneel Deepak Kamath · 2 shared papers, 2021–2022 · strength 0.30
  12. Carolina Torres · 3 shared papers, 2018–2019 · strength 0.27
  13. Jeffrey H. Becker · 1 shared paper, 2024 · strength 0.23
  14. Navin Viswakarma · 2 shared papers, 2019–2021 · strength 0.21
  15. Lawrence B. Schook · 2 shared papers, 2018–2019 · strength 0.17
  16. Jose Trevino · 1 shared paper, 2022 · strength 0.14
  17. David J. Bentrem · 1 shared paper, 2021 · strength 0.13
  18. Dinesh Thummuri · 1 shared paper, 2022 · strength 0.13
  19. Daohong Zhou · 1 shared paper, 2022 · strength 0.13
  20. Pier Cristoforo Giulianotti · 1 shared paper, 2021 · strength 0.12
  21. Megha Singhal · 1 shared paper, 2019 · strength 0.10
  22. Georgina E. Mancinelli · 1 shared paper, 2019 · strength 0.10
  23. Sam R. Grimaldo · 1 shared paper, 2019 · strength 0.10
  24. Ajay V. Maker · 1 shared paper, 2018 · strength 0.07
  25. David W. Dawson · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.